医学
骨关节炎
临床试验
不利影响
可视模拟标度
临床疗效
随机对照试验
外科
内科学
病理
替代医学
作者
Se Haeng Cho,Young Bok Jung,Sang Cheol Seong,Hyung Bin Park,Ki Yong Byun,Dong Chul Lee,Eun Kyoo Song,Jung Hwan Son
出处
期刊:PubMed
日期:2003-06-01
卷期号:35 (6): 212-6
被引量:49
摘要
To validate the clinical efficacy and safety of Lyprinol (a patented extract from Perna Canaliculus), a 5-LOX inhibitor in patients with osteoarthritis.In this multicenter trial, 60 patients with symptomatic osteoarthritis of the knee and hip were included to receive Lyprinol at a dose of 2 capsules twice a day. After a 4- and 8-week treatment period, the following parameters were analyzed: visual analogue scale; Lequesne functional index; global assessment by patients; global assessment by physician; and adverse effects.Lyprinol treatment led to significant improvement of the signs and symptoms of osteoarthritis as determined by all efficacy measures. After a 4- and 8-week treatment period, 53% and 80% (respectively) of patients experienced significant pain relief, and improvement of joint function. There was no reported adverse effect during this clinical trial.Lyprinol was very effective and is a promising anti-inflammatory product that relieves the signs and symptoms of osteoarthritis, without adverse effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI